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Chapter 1. Anthelmintic drugs 
 
 
 
1.1 INTRODUTION 
According to the Regulation (EC) No 470/2009 (1), „residues of 
pharmacologically active substances‟ means all pharmacologically active 
substances, expressed in mg/kg or µg/kg on a fresh weight basis, whether 
active substances, excipients or degradation products, and their 
metabolites which remain in food obtained from animals to which the 
veterinary medicinal product in question has been administered. 
The analysis of residues of chemicals in foods of animal origin is a 
relatively young discipline. A residue may be defined as a trace of a 
substance, present in a matrix after some kind of administration (e.g. 
veterinary practice or illegal use) to an animal. In all cases, 
concentrations levels in the ppb concentration range (ppb or µg kg−1) or 
even lower (ppt or ng kg−1) have to be detected (2). 
The substances involved may be divided into two major classes 
according to council directive 96/23/EC (3): group A and B substances. 
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ANNEX I  
GROUP A - Substances having anabolic effect and unauthorized 
substances  
 (1) Stilbenes, stilbene derivatives, and their salts and esters 
(2) Antithyroid agents 
(3) Steroids 
(4) Resorcylic acid lactones including zeranol 
(5) Beta-agonists 
(6) Compounds included in Annex IV to Council Regulation (EEC) No 
2377/90 of 26 June 1990 
There are no maximum residue limits for these substances because 
they are prohibited in food producing animals in the EU. 
GROUP B - Veterinary drugs and contaminants  
(1) Antibacterial substances, including sulphonomides, quinolones 
(2) Other veterinary drugs 
(a) Anthelmintics 
(b) Anticoccidials, including nitroimidazoles 
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(c) Carbamates and pyrethroids 
(d) Sedatives 
(e) Non-steroidal anti-inflammatory drugs (NSAIDs) 
(f) Other pharmacologically active substances 
(3) Other substances and environmental contaminants 
(a) Organochlorine compounds including PcBs 
(b) Organophosphorus compounds 
(d) Chemical elements 
(d) Mycotoxins 
(e) Dyes 
(f) Others 
Group B includes the veterinary drug or veterinary medicinal 
products (VMPs) for which maximum residue limit (MRLs) have been 
fixed. The safety and residue evaluation is carried out by the Committee 
for Veterinary Medicinal Products (CVMP) of the European Agency for 
the Evaluation of Medicinal Products (EMEA) in London, and is 
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supported by safety and residue experts, upon receipt of a valid 
application for the establishment of MRLs. 
MRLs, listed under European Commission Regulation 37/2010 (4), 
have been set for a number of anthelmintics in milk and edible tissues 
(muscle, liver, kidney and fat) with the aim of minimizing the risk to 
human health associated with their consumption.  
In general, anthelmintic residues cause no human health risk if 
veterinary drugs are properly administered and the recommended doses 
are correctly adhered to.  
However, there may be a concern that if withdrawal periods are not 
adhered to or if products are administered to animals in unapproved 
applications (e.g. administration to lactating species) those levels may 
exceed MRLs in foods.  
In addiction, whenever chemicals are used, especially with long 
term low dose exposure, toxicological, teratological and carcinogenetic 
effects must be considered.  
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Only a limited number of products are licensed for treatment of 
animals during the lactating period and have a MRL listed under 
European Commission Regulation 37/2010 (Table 1).  
The widespread availability of cheaper generic veterinary 
medicinal products and the development of drug resistance to the limited 
number of licensed products have increased the potential for off-label 
applications. 
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Table 1.  MRLs for anthelmintic drug residues in milk as listed under European 
Regulation 37/2010 
 
* provisional MRL of 45 ug/kg-1 in cattle and sheep milk (EMA/CVMP/584576/2010) 
Veterinary drug Marker Residue(s) MRLs (µg kg−1) 
Albedazole, 
albendazole 
sulphoxide, netobimin 
Sum of albendazole-sulphoxide, 
albendazole-sulphone and 
albendazole-sulphone amine expressed 
as albendazole 
100 
Fenbendazole, 
oxfendazole, febantel 
 
Sum of fenbendazole, fenbendazole-
sulphoxide and 
fenbendazole-sulphone expressed as 
fenbendazole-sulphone 
10 
Thiabendazole 
 
Sum of thiabendazole and 5-
hydroxythiabendazole 
100 
Morantel 
 
Morantel 50 
Oxyclozanide Oxyclozanide 10 
Eprinomectin 
 
Eprinomectin B1a 
 
20 
Moxidectin 
 
Moxidectin 40 
Closantel* Closantel 45 
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1.2  CLASSIFICATION OF ANTHELMINTIC DRUGS 
 
The first treatments used on animals for internal parasites date back 
to two centuries ago. These kind of „drugs‟ were quite rudimentary, since 
they derived from metals or plant extracts, and they worked by 
mechanical irritating the parasites from their predilection sites. 
In the mid-twentieth century, the introduction of phenothiazine and 
piperazine as veterinary anthelmintics did provide compounds with real 
activity against target parasite species and with acceptable tolerance in 
the host animal species.  
However, major progress was made between 1960 and 1980. In 
these 20 years, drugs with diverse structure, novel activity and enviable 
safety were produced for a global livestock industry. The discoveries of 
thiabendazole and levamisole provided compounds with in vivo potency 
at milligram (per kg of body weight) rather than gram dosages and, in the 
case of thiabendazole, led to the discovery of a group of structural 
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analogues, the benzimidazoles, with excellent broad-spectrum activity 
and safety.  
In 1981, a further major step forward was made in chemotherapy 
with the launch in the animal health market of ivermectin, which had 
activity in animals when administered at microgram per kg dosages, had 
excellent broad spectrum activity against nematodes and was also 
effective against several parasitic arthropods. 
The last 20 years have been spent refining existing molecules with 
niche activity (parasite and host specificity), improving delivery systems 
and worrying about the inexorable spread of drug resistance (5). 
Anthelmintics are antiparasite drugs used to treat infections with 
nematodes, cestodes and trematodes. They are of huge importance both 
for human tropical medicine and for veterinary medicine. 
There is an extensive number of antiparasitic agents licensed as 
veterinary drugs, such as the benzimidazoles (6) macrocyclic lactones, (7) 
and levamisole (8). Many of these drugs are licensed for the treatment of 
meat producing animals but not for dairy animals. 
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Antiparasite drugs have a great variety, with different chemical 
constitutions, functions and mechanisms of action. 
Anthelmintics may be separated into classes on the basis of similar 
chemical structure and mode of action (9). 
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1.3 PIPERAZINE  
 
This class of drugs was first used as an anthelmintic in the 1950‟s 
for the treatment of threadworms in children (White, 1953) (10). 
The importance of piperazines in designing effective drugs for 
intestinal and tissue-dwelling helminths was not recognized till 1947 
when scientists working at the Lederle Laboratories of the American 
Cyanamid Company discovered the antifilarial activity of 1,4-
disubstituted piperazines (11). 
Piperazines have heterocyclic ring structure containing two 
opposite nitrogen atoms (Fig.1). 
 
1.4 MODE OF ACTION 
 
Their mode of action is generally by paralyzing parasites, which 
allows the host body to easily remove or expel the invading organism. 
This process is mediated by its agonist effects upon the inhibitory GABA 
(γ-amino butyric acid) receptor. Its selectivity for helminths is because 
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vertebrates only use GABA in the CNS and the helminths' GABA 
receptor is a different isoform to the vertebrate's one. Its mode of action 
has primarily been studied in Ascaris suum.  
In A. suum it acts as a weak GABA-mimetic and causes a flaccid, 
reversible paralysis of body wall muscle (Martin, 1985) (12). 
 
 
 
 
 
Figure 1. Piperazine chemical structure 
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1.5 BENZIMIDAZOLES  
 
Benzimidazoles are anthelmintic drugs widely used for prevention 
and treatment of parasitic infections in agriculture and aquaculture. Some 
benzimidazoles have also found applications as pre- or post-harvest 
fungicides for control of a wide range of fungi affecting field crops, 
stored fruit and vegetables. 
They contain a common 1,2-diaminobenzene nucleus and most of 
them may also have a carbamate functional group. In general, 
Benzimidazoles are almost insoluble in water and slightly soluble in 
alcohols or chlorinated hydrocarbons. 
The first of this class, thiabendazole (TBZ), was discovered in 
1961 (Brown et al.) (13) and subsequently a number of further 
benzimidazoles were introduced as broad spectrum anthelmintics. TBZ 
has been widely used for the control of gastrointestinal nematodes, 
lungworms and as a fungicidal agent.  
After its introduction, a number of alternative drugs offering 
similar spectrums of activity came on the market, such as parabendazole 
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(PAR) (14), cambendazole (CAM) (15) mebendazole (MBZ) (16), and 
oxibendazole (OXI) (17). 
BZs with sulphide and sulphoxide, such as albendazole (ABZ) 
(18), fenbendazole (FBZ) (19) and oxfendazole (OFX) (20) functional 
groups were following introduced, offering a broader spectrum of activity 
and improved efficacy. These compounds were the first to be successfully 
used in the treatment of roundworms, lungworms, tapeworms and adult 
stages of liver fluke.  
Later on, in the 1983, was discovered triclabendazole (TCB) (21). 
This drug, unlike the other benzimidazoles, in the chemical structure has 
a chlorinated benzene ring but no carbamate group. This drug displays 
high efficacy against both immature and adult liver fluke (trematodes), 
but it is not effective against nematodes and cestodes. Since its 
introduction in the early 1980s, triclabendazole has become the main drug 
used to treat livestock infections with Fasciola hepatica. A recent study 
(22) has also showed the relative activity of its metabolites TCB-SO2 
(sulphone) and TCB-SO (sulphoxide) against flukicides.  
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1.6 MODE OF ACTION 
 
Different modes of action have been proposed for BZ‟s. Their 
anthelmintic efficacy, except for mebendazole, is due to their ability to 
interfere with the parasite‟s energy and inhibit the fumarate reductase. 
Consequently, this disturbs the adenosine triphosphate formation, 
because replaces the Krebs cycle in anaerobic way (Lacey et al.)(23). 
MBZ, instead, compromises the cytoskeleton through a selective 
interaction with β-tubulin (Borgers and De Nollin, 1975) (24). 
 
 
 
 
Figure 2. Benzimidazoles nucleus 
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1.7 TETRA-HYDRO-IMIDAZOLES 
 
Tetramisole (25) and levamisole (26) (Fig.3) (imidazothiazoles) 
with pyrantel (27) and morantel (28) (tetrahydropyrimidines) are 
nicotinic receptor agonists. Their precise mode of action has been 
carefully studied at the single-channel level on the body wall muscle 
preparation of A. suum. These compounds act selectively as agonists at 
synaptic and extrasynaptic nicotinic acetylcholine receptors (nAChR) on 
nematode muscle cells and produce contraction and spastic paralysis (29).  
The anthelmintic activity of tetramisole, a racemic mixture, resides 
in the l-isomer, levamisole. In the earliest studies Tetramisole was used 
(30) and later replaced by the more active levorotatory isomer LEV (31). 
It is commonly used in cattle, sheep, pigs, goats, and poultry to treat 
nematode infections; it has no activity against flukes and tapeworms. 
Levamisole has also immunostimulant effects (32) (33) at dosage 
rates higher than those used for anthelmintic activity, and it has been used 
both in humans and in animals in several diseases. The immunologic 
16 
 
enhancement is due by stimulating lymphoid tissue T-cell system, 
improving the production of lymphocyte active substances and increasing 
the phagocytosis of macrophage and neutrophil. Recently many authors 
have showed the antitumor activity of Levamisole in the colon cancer 
therapy (34) (35). 
            
 
 
Figure 3. Levamisole 
 
The Tetrahydropyrimidines are broad spectrum anthelmintics, 
expelling eelworm drugs, and they are suitable for various kinds of 
animal‟s gastrointestinal parasites. This class includes pyrantel, morantel 
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and hydroxyl pyrimidine. This last compound is a miracle drug for 
Trichiuris. 
The efficacy of pyrantel (Fig. 4) as a veterinary anthelmintic first 
emerged in 1966 (36) just one year after the imidazothiazoles had entered 
the market. It is available as a citrate, tartrate, embonate, or pamoate salt.  
                   
 
 
Fig.4 Pyrantel 
 
Morantel (Fig.5) (37) (1,4,5,6-tetrahydro-1-methyl-2-[2-(3-methyl-2-
thienyl) ethenyl pyrimidine) is a tetrahydro-pyrimidine anthelmintic, 
differing from the related analogue pyrantel by the presence of a methyl 
group on the thiophene ring. It is intended to treat roundworms and 
tapeworms. It is administered in lactating and non-lactating cattle as 
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morantel tartrate. The residues in milk must no exceed the limit of 50 
µg/kg fixed in the 37/2010 EC. 
           
 
Figure 5. Morantel 
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1.8  MACROCYCLIC  LACTONES 
 
The macrocyclic lactones (avermectins and milbemycins) are 
products, or chemical derivatives thereof, of soil microorganisms 
belonging to the genus Streptomyces. The avermectins in commercial use 
are ivermectin, abamectin, doramectin, eprinomectin, and selamectin. 
Commercially available milbemycins are milbemycin oxime and 
moxidectin.  
Avermectins are highly lipophilic substances and dissolve in most 
organic solvents, such as chloroform, acetone, cyclohexane and alcohols. 
The microorganism that produces the avermectins was isolated from a 
soil sample collected in Japan (38). 
The avermectins were initially detected in a program in which 
thousands of microbial fermentation products were tested in mice for 
activity against the nematode, Nematospiroides dubius. Among the few 
preparations showing activity in this assay, was the product of a 
microorganism isolated from soil by researchers at The Kitasato Institute 
(39). 
20 
 
The microorganism was classified as a new species of 
actinomycete, Streptomyces avermitilis. Its anthelmintic activity was 
shown to reside in 8 closely related macrocyclic lactones which were also 
found to possess activity against free-living and parasitic arthropods.  
One of the natural components, avermectin B1, is now being 
evaluated as a pesticide for the control of mites of citrus and cotton crops. 
A chemical derivative, 22,23-dihydroavermectin B1, or ivermectin, has 
been developed as an antiparasitic agent.  
 
 
Fig. 6 Avermectin 
 
 
MLs are large complex ringed structures (Fig.6); avermectins have 
a 16-membered macrocyclic ring, containing a spiroketal group, a 
benzofuran ring and disaccharide functionality or, in the case of 
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selamectin, have only a monosaccharide group. Milbemycins are 
structurally similar to avermectins but lack the disaccharide group. 
The macrocyclic lactones have a potent, broad antiparasitic 
spectrum at low dose levels. They are active against many immature 
nematodes (including hypobiotic larvae) and arthropods, but are no 
effective against trematodes and cestodes. 
Six avermectins and two milbemycins are currently licensed as 
veterinary drugs and insecticides. Abamectin (40) and ivermectin (41) are 
the best known, because of their long and extensive employment. MLs 
were initially investigated for treatment of parasitic infections in animals 
but their potential for use in human medicine was quickly identified; 
nowadays is still the first choice in human onchocerciasis (42). 
Ivermectin (43) and doramectin (44) may be used on all 
mammalian food producing species, with proscription in animals from 
which milk is produced for human consumption, whereas eprinomectin 
(45) can be administered on dairy cattle with an MRL set at 20 µg/kg. 
Approvals have been granted for injectable or oral (bolus) dosage forms 
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for some of these drugs in cattle, but it is common for these drugs to be 
applied topically.  
Some avermectins, including emamectin (46), have also been 
shown to be effective for the treatment of fishfin diseases such as sea lice 
in farm-raised salmon (47).   
Moxidectin is a synthetic milbemycin drug with similar properties 
to the avermectins; it has been approved for use in dairy cattle and sheep 
(48) and 40 µg/kg is the MRL fixed for milk. 
Selamectin (49) is used both as a topical insecticide and 
anthelmintic on dogs and cats. It controls outbreaks of fleas, heartworm, 
hookworms, roundworms, and ear mites. Selamectin is not approved for 
human use. 
Table 2. Macrocyclic lactones 
 
COMPOUND R1 R2 R3 
Abamectin B1a OH H CHCH3CH2CH3 
Emamectin B1a OH H C6H11 
Eprinomectin B1a C6H5COOHCH3NH H CHCH3CH2CH3 
Doramectin NHCOCH3 H  CHCH3CH2CH3 
Ivermectin (H2B1a) OH H CHCH3CH2CH3 
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1.9 MODE OF ACTION 
 
The mode of action of macrocyclic lactones (50) is to selectively 
paralyze the parasite by increasing muscle Cl- permeability, specifically 
avermectins act by binding to glutamate-gated chloride channel receptors 
in nematode and arthropod nerve cells. This causes the channel to open, 
allowing an influx of chloride ions. Different chloride channel subunits 
may show variable sensitivity to macrocyclic lactones and different sites 
of expression, which could account for the paralytic effects of 
macrocyclic lactones on different neuromuscular systems at different 
concentrations. The macrocyclic lactones paralyze the pharynx, the body 
wall, and the uterine muscles of nematodes.  
The effect is similar to that of GABA, but is essentially 
irreversible. In tissues containing GABA receptors, the avermectin-
dependent conductance increase is often accompanied by a loss of 
sensitivity to exogenously applied GABA and this GABA blocking action 
may be responsible for the transient tremor observed in mammals. 
Especially important are the glutamate-gated chloride channels of insect 
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and nematode skeletal muscle, which may mediate avermectin-induced 
muscle paralysis in these organisms.  
Mammals do not have glutamate-gated chloride channels; the 
macrocyclic lactones have a low affinity for other mammalian ligand-
gated channels and do not readily cross the blood-brain barrier. 
Many studies on biological activity and toxicity of avermectins 
have been done. MLs are relatively safe for approved species such as 
cattle and sheep. Non teratogenic affects have been observed in these 
animals (51). However, teratogenic and maternotoxic effects have been 
reported in mice, rats and rabbits. Toxic effects have been noticed in 
dogs, especially collies, because they are claimed to have more sensitivity 
to ivermectin then other breeds (52). These dogs lack a protein (P-
Glycoprotein), which is responsible for pumping out ivermectin and other 
drugs from the brain. This is caused to a mutation in the multi-drug 
resistance gene (MDR1), which allows the entrance of toxic substances in 
the blood-brain barrier.  
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1.10 SALICYLANILIDES AND PHENOL DERIVATES  
 
The discovery of salicylanilides as anthelmintic agents owes its 
origin to research for new antiseptics. These anthelmintics all have a 
salicylanilide structure and share common features relating to their mode 
of action, pharmacokinetics and toxicity. 
Salicylanilide is a chemical compound which is the amide of 
salicylic acid and aniline (Fig. 7). It is classified as both a salicylamide 
and ananilide.  
Derivatives of salicylanilide have a variety of pharmacological 
uses. Chlorinated derivatives including niclosamide, oxyclozanide, and 
rafoxanide are used as antitrematodal and anticestodal agents. 
Brominated derivatives including dibromsalan, metabromsalan, 
and tribromsalan are used as disinfectants with antibacterial and 
antifungal activities. 
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Fig.7 Salicylanilide structure 
 
 
Since the late nineteenth century antibacterial properties of phenol 
derivatives were commonly known. Further studies led to the introduction 
of several phenol derivatives among which bithionol and 
hexachlorophtene. These compounds along with niclofolan and 
niclosamide were later used to eradicate tapeworms and liver flukes from 
humans and domestic animals (53). 
Niclosamide is a highly effective molluscicide and taenicide, 
which was marketed in 1960. It soon became the drug of choice for 
treating all gastrointestinal tapeworm infections in humans and domestic 
animals. This molecule (Fig. 8), both in adults and children, is lethal upon 
contact to taenia solium and saginata but has no effective on mature 
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proglottides. Niclosamide has also some activity against paramphistomes 
in ruminants (54) and, in the last year, many studies in human medicine 
have showed its antineoplastic mechanism in leukaemia (55) and colon 
cancer (56). 
      
Fig. 8 Niclosamide 
 
The pharmacology of drugs used for the treatment of trematodal 
disease of domestic animals has been afforded much less attention than 
the antinematodal drug. 
A major group of flukicidal drugs became available when the activity of 
oxyclozanide (Fig. 9) against Fasciola hepatica was described in 1966 
(57). Although niclosamide itself possesses two chloro groups, one each 
in both the benzene rings, scientists considered prominent to study the 
characteristics of other chloro derivatives. 
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With its five chloro groups, Oxyclozanide (58) is definitely the 
most used in the treatment and control of fascioliasis in ruminants and, 
until now, it was the exclusive flukicide licensed in lactating ruminants. 
The MRL in milk is 10 µg/kg. 
                  
Fig. 9 Oxyclozanide 
 
 
Recently the Committee for Medicinal Products for Veterinary Use 
of the European Medicines Agency recently adopted a positive opinion 
recommending the establishment of provisional (expire on the beginning 
of 2013) maximum residue limits of 45 µg/kg for another flukicide drug, 
Closantel, in cow and sheep milk.  
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Closantel (59), among with Rafoxanide (60), has a highly 
antitrematodal activity. This is due to the presence of iodine groups in the 
benzene ring of the salicylanilides (Figures 10-11). 
 
       
 
Fig. 10 Closantel 
 
    
 
Fig. 11 Rafoxanide 
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     These compounds are used extensively for the control of Haemonchus 
spp. and Fasciola spp. infestations in sheep and cattle and Oestrus ovis in 
sheep in many parts of the World.  
Rafoxanide has MRLs set only for muscle, fat, liver and kidney; this drug 
cannot be used in animals from which milk is produced for human 
consumption. 
Nitroxynil (3-iodo-4-hydroxy-5-nitrobenzonitrile) is a phenol 
derivative (61) used in cattle and sheep for the control of fascioliasis. 
When compared with other fasciolicides, this compound shows high 
activity against both adult and immature liver flukes. The European 
Union has established Maximum Residue Limits (MRLs) for the marker 
residue nitroxynil in the tissues liver, kidney, muscle and fat, but no MRL 
presently is available in milk. 
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Fig. 12 Nitroxynil 
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1.11 MODE OF ACTION 
 
The chemical structure salicylanilides and nitroxynil illustrates that 
each anthelmintic molecule possesses a detachable proton (H). These 
molecules are high lipophilic and may shuttle protons across membranes, 
particularly the inner mitochondrial membrane. The mechanism of action 
of the proton ionophores has been assumed to be to selectively uncouple 
oxidative phosphorilation in parasite mitochondria (62). 
The anthelmintics that have the longest half-life in the body are the 
salicylanides and nitroxynil. (63)  
This is explained by their strong plasma protein binding which is 
more than 99% for the salicylanilides (64) and 98% for nitroxynil (65). 
The selective mode of action of these highly protein-bound anthelmintics 
may be explained, in part, by their effect against blood-sucking parasites, 
concentrating the anthelmintic in the parasite without the high tissue 
levels being produced in the host. The high level of protein binding may 
explain the selective effect of these agents, and the fact that well bled out 
carcasses have low tissue residue levels. Thus the mode of action of this 
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group of anthelmintic involves the selective delivery of the proton 
ionophores to the parasite because of the high level of plasma-protein 
binding. 
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1.12 BENZENESULPHONAMIDES 
 
Clorsulon (66) is a compound belonging to the 
benzenesulphonamide family which is recommended for the control of 
adult liver flukes in cattle. Frequently is used in association with 
ivermectin to extend the antiparasite efficacy against roundworms and 
mites. Throughout the European Union the administration of the 4-
Amino-6-(trichlorovinyl)-1,3-benzenedisulfonamide (Fig. 13) to dairy 
cows is not allowed. The Commission Regulation 37/2010 fixed the 
maximum residue limits only for bovine muscle (35 µg/kg), liver (100 
µg/kg) and kidney (200 µg/kg). 
 
        
Figure 13. Clorsulon 
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Clorsulon inhibits the enzymes implicated in the glycolytic 
pathway, the primary source of energy in flukes. Further investigations 
indicated that clorsulon is a competitive inhibitor of 3-phosphoglycerate 
kinase and phosphor-glyceromutase and blocks the oxidation of glucose 
to acetate and propionate. The sulphonamide also depresses the ATP 
levels in the trematodes (67).  
A neuromuscular action for clorsulon is unlikely because the 
flaccid paralysis it induces is essentially long-term in nature. The gradual 
suppression of motility observed would be compatible with a depletion of 
energy reserves following glycolysis inhibition.   
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Chapter 2. Methods for the determination of residues in 
food stuffs 
 
 
Residue methods must be able to isolate and detect very small 
amounts (part per-billion or lower) of an analyte in a variety of complex 
matrices. The physical and chemical properties of the drugs of interest as 
well as the accompanying matrix must be evaluated to determine the 
optimal procedures for extraction, isolation and detection at residue 
levels.  
Because of the potential health risk from exposure to some animal 
drugs and the low levels at which they are found in edible products, 
monitoring the food supply for these residues is an important analytical 
challenge. Tolerances or maximum residue levels are established for 
drugs that are allowed for use in food animals. For these drugs, analytical 
methods need to be able to accurately determine if a residue is present 
above these set limits.  
For some compounds (e.g., chloramphenicol, nitrofurans and 
malachite green) the health concerns are such that no amount of residue is 
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allowed. In these cases, analytical methods need to be as sensitive and 
selective as possible to monitor for any residue that might be present. 
Several broad types of analytical methods can be described; these 
include screening, determinative and confirmatory procedures. 
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2.1 SCREENING METHODS 
 
Screening methods are designed to be rapid, easy to use tests that will 
give a positive or negative response for a drug at a given concentration 
level in a matrix. 
Only those analytical techniques, for which it can be demonstrated in 
a documented traceable manner that they are validated and have a false 
compliant rate of < 5 % (β-error) at the level of interest, shall be used for 
screening purposes in conformity with Directive 96/23/EC (3). In the case 
of a suspected non-compliant result, this result shall be confirmed by a 
confirmatory method. 
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2.2 CONFIRMATORY METHODS 
 
Determinative methods are designed to separate, quantify and perhaps 
provide some qualitative information on the analyte of interest. For many 
of the drugs used in animal husbandry, the determinative method of 
choice is LC with UV detection using a variable wavelength or diode 
array detection system. 
Confirmatory methods for organic residues or contaminants shall 
provide information on the chemical structure of the analyte. 
Consequently methods based only on chromatographic analysis without 
the use of spectrometric detection are not suitable on their own for use as 
confirmatory methods. However, if a single technique lacks sufficient 
specificity, the desired specificity shall be achieved by analytical 
procedures consisting of suitable combinations of clean-up, 
chromatographic separations and spectrometric detection. 
The COMMISSION DECISION 2002/657 EC (68), implementing 
Council Directive 96/23/EC concerning the performance of analytical 
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methods and the interpretation of results, is probably the key document of 
legislation to be consulted by analytical laboratories in veterinary residue 
control. 
It lists performance criteria and other requirements for separation and 
detection techniques for both screening and confirmatory methods. 
It provides for the progressive establishment of minimum required 
performance limits (MRPL) of analytical method for substances for 
which no permitted limit has been established and in particular for those 
substances whose use is not authorised, or is specifically prohibited in the 
Community, in order to ensure harmonised implementation of Directive 
96/23/EC. 
In this Commission Decision all the performance characteristics 
that can be attributed to an analytical method have been specified. This 
includes definitions and descriptions how to assess recovery, 
repeatability, ruggedness, and detailed requirements for MS detection and 
identification of targeted substances. Decision limit (CC-alfa), and 
detection capability (CC-beta), aimed at replacing limit of detection 
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(LOD) and limit of quantitation (LOQ), are addressed in this document 
and have received broad attention(69).  
The limit of detection (LOD) for any analytical procedure, the 
point at
 
which analysis is just feasible, may be determined by a statistical
 
approach based on measuring replicate blank (negative) samples or by an
 
empirical approach, consisting of measuring progressively more dilute
 
concentrations of analyte. The limit of quantitation (LOQ), or
 
concentration at which quantitative results can be reported with a high
 
degree of confidence, may likewise be determined by either approach 
(70). 
Decision limit (CCα) represents the limit at and above which it can be 
concluded with an error probability of that a sample is non-compliant. 
Detection capability (CCβ) means the smallest content of the substance 
that may be detected, identified and/or quantified in a sample with an 
error probability of. In the case of substances for which no permitted limit 
has been established, the detection capability is the lowest concentration 
at which a method is able to detect truly contaminated samples with a 
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statistical certainty of 1−β. In the case of substances with an established 
permitted limit, this means that the detection capability is the 
concentration at which the method is able to detect permitted limit 
concentrations with a statistical certainty of 1− β (68). The following 
methods or method combinations are considered suitable for the 
identification of organic residues or contaminants for the substance 
groups indicated: 
 
 LC or GC with mass-spectrometric detection (group a and b) 
 LC or GC with IR spectrometric detection (group a and b) 
 LC-full-scan DAD (group b) 
 LC -fluorescence(group b) 
 2-D TLC - full-scan UV/VIS(group b) 
 GC-Elektron capture detection(group b) 
 LC-immunogram(group b) 
 LC-UV/VIS (single wavelength) (group b) 
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In addition to determining how much of a drug residue is present, 
confirmation of identity is also required for a complete analytical 
regulatory package. Mass spectrometry (MS) is ideally suited for this 
qualitative analysis due to its inherent selectivity and sensitivity. Certain 
criteria, in terms of the number and quality of ions monitored for any 
given compound, need to be met to definitively determine if a residue has 
been positively identified.  
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2.3 MULTICLASS METHODS 
 
An emerging trend in veterinary drug residue analysis is the 
development of methods that are capable of monitoring a wide variety of 
residues, regardless of drug class, in a single sample. Screening and 
confirmatory data are collected by MS; some methods also provide 
quantification of residues. Both ion trap and triple quadrupole MS-MS 
instruments have been successfully utilized. Several multi-class 
veterinary drug residues methods have been reported in recent years. In 
the matter of anthelmintics residues, Kinsella et al. (71) have developed a 
simple but effective multi-class method for the detection and 
quantification of 38 anthelmintics residues in bovine milk and liver. This 
is a QuEChERS (“quick, easy, cheap, effective, rugged and safe”) 
method. Recently another method was optimized by Whelan et al. (72) 
using UHPLC–MS/MS with fast polarity switching. The method allows 
the detection of anthelmintic drug residues in milk to <1μg kg−1. 
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This method has been used for these studies on residues of antiparasite 
drugs allowed and not in milk and dairy products.  
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Chapter 3. Investigation of the persistence of levamisole 
and oxyclozanide in milk and fate in cheese 
 
 
Anthelmintic drugs are widely used in veterinary medicine for 
protecting or treating animals mainly against gastrointestinal nematodes 
and trematodes. Levamisole is effective against lungworms and 
roundworms at both larval and adult stages while oxyclozanide is mainly 
used in the treatment of adult stages of liver fluke.  
The European Regulation 37/2010 (4) has set Maximum Residue 
Limit in milk  for oxyclozanide (10 µg kg
-1 
) but no MRL is fixed for 
levamisole. The widespread availability of cheaper generic veterinary 
medicinal products and the development of drug resistance to the limited 
number of licensed products have increased the potential for off-label 
applications (73).  
However, levels detected in food are generally well below toxicity 
thresholds and pose no risk to the consumers, but there are concerns 
about the presence of residues in milk.  
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No data has been published in peer reviewed literature concerning 
the fate of these residues during cheese production. The knowledge 
generated from this study is particularly useful should these drugs be 
accidentally administered to dairy cows.   
 
3.1 SUMMARY 
 
 The aim of this study was to investigate the persistence of 
oxyclozanide and levamisole residues in bovine milk after treatment with 
a combination product and their subsequent fate during cheese 
production. Animals were milked twice daily up to 16 days post 
treatment.  Soft (3 d ripening), hard (35 d ripening) and whey cheeses 
were produced from the milk samples collected from first two milkings.  
Milk and cheese samples were subsequently analysed by UPLC-MS/MS.  
Highest levels of levamisole (<600 µg/kg
-1
) and oxyclozanide (<25 
µg/kg
-1
) were determinate at first and third milking  respectively. 
Levamisole residues were found to concentrate in all cheese types.  
There was a three fold concentration effect for levamisole in mature 
48 
 
cheese.  Oxyclozanide residues were found to occur at lower levels in soft 
and hard cheese than milk with a 10-fold concentration in whey cheese 
compared to milk.   
Residues were found at higher levels in cheeses compared to the 
milk. The results of this study demonstrate that levamisole and 
oxyclozanide residues are rapidly excreted in dairy cows and milk is 
compliant after few days, but  survive the fermentation process to persist 
in cheese. 
 
3.2 MATERIALS AND METHODS 
3.2.a Animal Studies 
 
Six Friesian cows weighing between 400 and 500 kg were selected 
for the study.  The six cows were treated with the maximum dose (150 
mL for animals 300 Kg and over) of TOLOXAN, containing levamisole 
(5mg kg
-1
 bodyweight) and oxyclozanide (10mg kg
-1
 bw).  The first milk 
sample was taking at 6 p.m., 9.5 h after administration.  Milk samples 
were subsequently taken from the animals twice daily, morning (6 a.m.) 
49 
 
and evening (6 p.m.) over a 16 days period and the samples were frozen 
(-20 °C) until analysis. 
Mature, soft and whey cheese were produced from the first two 
milkings collected 9.5 and 21.5 h after administration by the following 
procedure.  Pooled raw milk from the six animals was collected (60 L) 
and heated to 38 °C, a curdling agent (cagliodoro) was added and kept for 
30 min.  The curdle was then broken and kept for 15 min after which the 
curdle and liquid whey were separated.  The curdle was then placed in a 
mould and the surface was salted to produce soft cheese after 3 d of 
maturation.  Half of the soft cheese was refrigerated for 35 d to produce 
mature cheese.  The liquid whey was boiled and placed immediately in a 
mould to obtain the whey cheese. All samples were frozen (-20 °C) until 
analysis. 
3.2.b Materials and Reagents 
 
Pre-weighed 50 mL polystyrene centrifuge tubes containing 4 g 
anhydrous (anh.) magnesium sulphate (MgSO4) and 1 g sodium chloride 
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(NaCl) (Tube 1), and 1.5 g anh. MgSO4 and 0.5 g C18 (Tube 2) were 
obtained from UCT, Inc. (Bristol, PA; USA).   
 
3.2.c Extraction and clean-up 
 
As described in Whelan et al. (72), milk samples (10 g ± 0.1 g) 
were weighed into centrifuge tubes (50 mL) and fortified with internal 
standard and left to sit for 15 min.  Cheese samples (4 g ± 0.04 g) and 
Millipore water (6 g ± 0.06 g) were weighed into centrifuge tubes (50 
mL) and placed in a water bath at 50 °C until the cheese and water 
become homogeneous, they are then fortified with internal standard and 
left to sit for 15 min.  MeCN (12 mL) was added to tube one containing 
MgSO4 (4 g) and NaCl (1 g). The contents of tube one was added to the 
sample and shaken immediately to extract the residues into the MeCN 
layer. The sample was centrifuged for 12 min at 3,500 rpm (959 g).  A 
dispersive-SPE cleanup step was performed by pouring the supernatant 
from tube one into tube two (50 mL) containing MgSO4 (1.5 g) and C18 
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(0.5 g).  The samples were vortexed for 30 s and centrifuged for 10 min at 
2,500 rpm (489 g).  The supernatant (6 mL) and DMSO (0.25 mL) were 
added to a starstedt tube (15 mL) and vortexed for one min.  The MeCN 
layer was evaporated under nitrogen at 50 °C to 0.25 mL.  Extracts were 
filtered through 0.2 µm PTFE syringe filters (Whatman Rezist) and 
injected onto the UPLC-MS/MS system. Any samples that fell outside the 
calibration range were diluted in negative milk and reanalysed. 
 
3.2.d UPLC-MS/MS analysis  
 
Chromatographic separations were performed using a Waters 
(Milford MA; USA) Acquity UPLC system, the column used was a 100 
mm × 2.1 mm i.d., 1.8 m, Acquity HSS T3, with an in-line filter unit 
with 0.2 µm stainless steel replacement filters (Waters).  The column 
oven was maintained at a temperature of 60 ºC and the Acquity pump was 
maintained at a flow rate of 0.6 mL/min.  Analytes were separated using 
the following gradient elution comprising of mobile phase A, 0.01% 
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HOAc in water:MeCN (90:10 v/v) and mobile phase B, 5mM ammonium 
formate in MeOH:MeCN (75:25, v/v).  The gradient profile was as 
follows: 0 – 0.5 min, 100% A; 5 min, 50% A; 7 min, 10% A; 8.5 min, 
10% A; 8.51 min, 0% A; 9.5 min, 0% A; 9.51 min, 100% A; 13 min 
100% A (72).  
A Waters Quattro Premier XE mass spectrometer was used to 
quantify the veterinary drug residues found in the milk samples  The 
electrospray ionisation (ESI) UPLC-MS/MS system was controlled by 
MassLynx software and chromatographic data was processed using 
TargetLynx Software (both from Waters).  Injection volume was 2 µL.  
The analytes and internal standards (Table 3) were tuned on the UPLC-
MS/MS and the optimum conditions were obtained during tuning and 
they were input into the MS settings.  The following transitions were 
input into multiple reaction monitoring (MRM) windows, 
210.10183.08 (m/z), d5-levamisole; 204.93122.89 (m/z) and 
204.93177.94 (m/z), levamisole; 212.0592.00 (m/z), salicylanilide; 
397.80175.75 (m/z) and 397.80201.80 (m/z), oxyclozanide.  d5-
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Levamisole retention time 2.82 min and levamisole retention time 2.83 
min were input to MRM channel 1 and detected in positive ion mode, 
salicylanilide, retention time 5.95 min and oxyclozanide, retention time 
6.83 min were input to MRM channel 2.  The MRM‟s were time-
sectored; dwell time, inter-scan delay and inter-channel delays were set to 
get maximum response from the instrument.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Table 3. UHPLC condition. Analytes and internal standards. 
 
ANALYTE 
tR 
(min) 
Transition 
(m/z) 
Cone 
(V) 
CE 
(V) ESI Polarity 
IS 
 
Levamisole D5 
 
N
N S
D D
D
D D  
 
1.58 
 
 
 
 
 
 
 
 
210.10183.08 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
20 
 
 
 
 
 
 
 
 
+ 
 
 
 
 
 
 
 
 
IS 
 
 
 
 
 
 
 
 
Levamisole 
 
N
N S  
 
  
1.59 
 
 
 
 
 
 
 
204.93122.89 
204.93177.94 
 
 
 
 
 
 
35 
35 
 
 
 
 
 
 
27 
14 
 
 
 
 
 
 
+ 
+ 
 
 
 
 
 
 
LEVA-D5 
 
 
 
 
 
 
 
Salicylanilide 
 
N
O
HOH  
 
5.65 
 
 
 
 
 
 
 
212.0592.00 
 
 
 
 
 
 
 
35 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
IS 
 
 
 
 
 
 
 
Oxyclozanide 
 
N
Cl
H
O
OH CH3
CH3
OH
Cl
Cl
 
 
6.63 
 
 
 
 
 
 
 
 
397.80175.75 
397.80201.80 
 
 
 
 
 
 
 
32 
32 
 
 
 
 
 
 
 
26 
20 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
 
SALI 
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3.2.e Calibration 
 
Levamisole, oxyclozanide and salicylanilide were purchased from 
Sigma-Aldrich.  d5-Levamisole was purchased from Witega Laboratories.  
Primary stock standard solutions were prepared at concentrations of 4 and 
2 mg/mL for oxyclozanide and levamisole respectively.  Internal 
standards (salicylanilide and d5-levamisole) were prepared at 
concentration of 1 mg/mL.  d5-Levamisole was prepared in deuterated 
methanol (in case of deuterium exchange in solution) and the remaining 
powders were prepared in methanol.  
Extracted matrix calibrants were prepared by fortifying negative 
milk samples prior to extraction with working standard mixes, prepared at 
the following concentrations (in µg/mL):  10, 5 (Std 7) 5, 4 (Std 6),  for 
levamisole and oxyclozanide respectively and 2 (Std 5), 1 (Std 4), 0.5 
(Std 3), 0.2 (Std 2), and 0.1 (Std 1) for both analytes. Matrix-matched 
calibration curves were prepared by fortifying matrix blanks before 
extraction with 100 µL of the standards to give working standard curves 
in the sample equivalent range of 1 to 100 and 1 to 50 µg/kg
  
for 
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levamisole and oxyclozanide respectively. An additional four blank 
matrix samples (recovery controls) were fortified after extraction, two 
with Std 2 (50 µL) and two with Std 5 (50 µL) to monitor for loss of 
analytes during extraction.  
3.2.f Development of the method  
 
The extraction, clean up procedure and UPLC-MS/MS method 
used in this investigation were developed previously (72).  The extraction 
and clean-up method did not require modifications as the method 
performance was satisfactory.  This was demonstrated for levamisole by 
participating in a proficiency study.  As this was not a multi method and 
the sensitivity of levamisole and oxyclozanide was not critical, it was 
possible to reduce the injection volume from 5 to 2 µL and still detect sub 
µg/kg
 
levels.  This resulted in an extended linear range from 1 – 50 µg/kg 
to 1 – 100 µg/kg for levamisole, and oxyclozanide remained 1 – 50 µg/kg 
with an improvement in the r
2 
value due to the reduced amount of matrix 
injected onto the system.  A preliminary run was carried out to determine 
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the concentration of the analytes in the samples.  The samples were then 
diluted in negative milk samples to fit the calibration range and the 
samples were re-extracted.  
The method was extended to cheese samples. The only 
modification was to the initial sample, 4 g of cheese and 6 g of water was 
added to the centrifuge and the sample was heated to 50 
o
C.  This resulted 
in a liquid suspension of cheese and water. The cheese suspension was 
then treated the same as the milk samples.  
 
3.3 RESULTS AND DISCUSSION 
3.3.a Levamisole and oxyclozanide residues in bovine milk 
 
There are surprising reports in literature of the persistence of 
levamisole residues in the milk of dairy cows after oral administration.  
Archambault et al. (74) investigated the persistence of levamisole in dairy 
cows after a subcutaneous injection (10 mg/kg bw).  The analytical 
method employed was only to measure levamisole residues to the limit of 
detection (LOD) of the assay, 100 µg/kg. Levamisole residues persisted 
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for approximately 12 d above the LOD post treatment.  Osterdahl et al. 
(75) treated cows (n = 42) infected with lungworm by an intramuscular 
injection (7 mg/kg bw).  Levamisole residues were less than the LOD, 40 
µg/L in all animals by 29 h post treatment.  De Ruyck et al. (76) treated 
cows (n = 4 each dose) topically with 10 and 20 mg/kg bw levamisole 
and levels declined to 21 and 83 µg/L
 
respectively by 79 h post treatment.  
At 7 h post-treatment, mean concentrations of levamisole residues were 
1896 (low dose) and 6027 µg/kg (high dose).  Paulson and Feil (77) 
treated dairy cows with oral (n = 1) and s.c. injectable doses (n = 1) with 
radiolabelled levamisole (8 mg/kg bw).  Highest concentrations after oral 
and subcutaneous doses were 191 and 208 µg/kg, respectively.  
Levamisole residues were measurable at approximately 1 µg/kg 
(levamisole parent drug) after both treatments.  Simkins et al. (78) carried 
out an extensive study in four groups of animals (n = 5 animals per 
group), which were treated with different formulations, oral drench, 
pellets, bolus and subcutaneous injection containing 8 mg/kg bw 
levamisole.  Levamisole residues were less than 10 µg/kg at 48 h for all 
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formulations.  Highest levamisole residues were detectable at 12 h post-
treatment: oral dose (240 to 750 µg/kg), pellet (160 to 900 µg/kg), bolus 
(220 to 840 µg/kg) and s.c injection (140 to 830 µg/kg).   
In this study, dairy cows (n = six) were treated with a combination 
product containing levamisole and oxyclozanide.  Milk samples were 
collected at morning (6 a.m.) and evening (6 p.m.) milking for 16 d post-
treatment and analysis was carried out by UPLC-MS/MS.  In agreement 
with previous studies, highest levels of levamisole residues were detected 
at the first milking and ranged from 108 to 586 µg/kg (Figure 14).  
Levamisole residues were found to be detectable at above the limit of 
reporting for levamisole (CC = 0.83 µg/kg) (72).  Residues of 
levamisole were <LOR on the 11
th
, 7
th
, 8
th
, 7
th
, 9
th
 and 8
th
 milking for cow 
one to six respectively.  The results of the study show that using LC-
MS/MS technology that levamisole residues were compliant 130 h post-
treatment.   
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Figure 14. Depletion profile of residues in bovine milk (A-F). Animal 1 to 6 respectively. 
Scale for Levamisole (left) and oxyclozanide (right) 
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 (E) 
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Only two papers have been reported on the persistence of oxyclozanide in 
milk.  Fujinuma et al. treated cows orally with 10 mg/kg bw oxyclozanide 
and residues were detectable until 30-47 h above 1 µg/kg (79).  Residues 
were typically at <10 µg/kg in all animals at all time-points.  Bluthgen et 
al. treated cows orally with 10 mg/kg bw oxyclozanide and residues were 
detected at 130 µg/kg at 48 h post treatment and 10 µg/kg at the 
prescribed withholding period of 120 h (80).   
In this study the highest levels of oxyclozanide ranged between 8 
and 24 µg/kg and were determined at the third milking.  Oxyclozanide 
residues were <1 µg/kg at 13
th
, 8
th
, 11
th
, 11
th
, 9
th
, and 10
th
 milking for 
animal one to six respectively.  Residues were below the MRL (10 µg/kg) 
at 8
th
, 7
th
, 4
th
 and 5
th
 milking for cows one, four, five and six, and below 
the MRL for all time points for cows two and three.  
The seventh and 12
th
 milking for animal one and three respectively 
were at higher concentrations than the previous samples in the depletion 
profile.  These samples were reanalysed to ensure results were correct and 
repeat analyses confirmed previous results.  The results were further 
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verified as the concentration of levamisole in the samples was as 
expected in the depletion profile.   
 
 
Table 4. Depletion of Levamisole and Oxyclozanide in Milk – average of 6 cows  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
point 
Levamisole Oxyclozanide 
 
 CC 
Levamisole 
MRL 
Oxyclozanide 
 ppb ppb µg kg
-1
 µg kg
-1
 
0 0,00 0,00 0,83 10 
0,5 339,87 3,23 0,83 10 
1 113,08 7,50 0,83 10 
1,5 36,14 10,83 0,83 10 
2 12,24 9,18 0,83 10 
2,5 6,07 7,57 0,83 10 
3 3,13 5,14 0,83 10 
3,5 1,68 7,31 0,83 10 
4 1,44 4,14 0,83 10 
4,5 0,78 1,87 0,83 10 
5 0,59 1,48 0,83 10 
5,5 0,42 0,99 0,83 10 
6 0,35 1,20 0,83 10 
6,5 0,29 0,69 0,83 10 
7 0,18 0,78 0,83 10 
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Figura 15. depletion of levamisole (A) and oxyclozanide (B) - average in the 6 cows 
 
 
(A) 
 
 
 
(B) 
 
 
 
 
 
66 
 
3.3.b FATE OF RESIDUES IN CHEESES 
 
Three types of cheese were produced from pooled milk of the six 
animals from the first two milkings 9.5 and 21.5 h after administration; 
soft, mature and whey cheese.  The cheese samples were produced from 
milk incurred with levamisole and oxyclozanide. 
 
Levamisole residues in cheese 
 
In general, the amount of levamisole residues found in the soft, 
mature and whey cheeses produced from the first two milking had similar 
patterns (Figure 14).  The concentration of levamisole in the pooled milk 
was 108 and 30 µg/kg for the first and second milking respectively.  The 
cheeses produced from the first milking had the following concentrations: 
290, 136 and 165 µg/kg for mature, whey and soft cheese respectively.  
In the cheese produced from the second milking 70, 38 and 52 µg/kg 
levamisole residues were detected in the mature, whey and soft cheese 
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respectively.  The values observed in cheese deserve careful attention as 
the concentration was higher than that found in milk.  The results indicate 
that the levamisole residue binds more strongly to the fat in the curdle 
than the proteins in the whey.  Levamisole residues concentrated in 
mature cheese samples as water content decreased.  The results found 
indicate that levamisole residues survive the fermentation process and the 
whey heat treatment and are stable during storage. 
 
Figure 14. Depletion of levamisole in cheeses 
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Oxyclozanide residues in cheese  
 
The levels of oxyclozanide found in mature, whey and soft cheese 
produced from the first two milkings indicates oxyclozanide is stable 
during storage and survives the fermentation process (Figure 15).  The 
concentration of oxyclozanide in the pooled milk was 7.0 and 13.4 µg/kg 
for the first and second milking respectively.  In the cheese produced 
from the first milking 6.7, 32.1 and 3.6 µg/kg oxyclozanide residues were 
detected in the mature, whey and soft cheese respectively.  In the cheese 
produced from the second milking 6.2, 41.9 and 5.6 µg/kg oxyclozanide 
was detected in mature, whey and soft cheese respectively.  Oxyclozanide 
residues were found to 10-fold concentrate in whey cheese, which is 
likely due to strong binding of acidic drugs residue to the proteins in the 
whey.   
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Figure 15. Depletion of oxyclozanide in cheeses 
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3.4 CONCLUSIONS 
 
 This study showed that levamisole and oxyclozanide are rapidly 
excreted in milk and residues are compliant after the 11th and 13
th
 
milkings, respectively.  Combination products containing levamisole and 
oxyclozanide are currently not allowed for the treatment of dairy animals 
and the results of this study show the consequences of hypothetical illegal 
use. Levamisole is well absorbed after oral administration as seen in 
Table 5. However, the results indicate that a short withdrawal period 
would be needed to ensure milk is compliant in the event that a MRL is 
set for levamisole.  Presently, no MRL is set for levamisole and detection 
of its residues in milk or dairy products will deem a sample non-
compliant.  This study also shows levamisole and oxyclozanide are stable 
during storage and survive the fermentation process with an increase in 
concentration compared to the concentration found in milk.  
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Chapter 4. Persistence of nitroxynil residues in bovine 
milk by ultra performance liquid chromatography 
tandem mass spectrometry (UPLC/MS-MS)  following a 
single administration in the dry period. 
 
 
 
4.1 SUMMARY 
Nitroxynil (61) is a halogenated phenol used to control fascioliasis 
in cattle and sheep. 35 pregnant dairy cows were treated in this study with 
a nitroxynil 340 mg/ml solution for injection at the recommended dose of 
10 mg/nitroxynil per kg body weight at the start of the dry period, 53 to 
74 days before the expected calving. Calving occurred between 43 days 
and 79 days after treatment. Subsequently, the concentrations of 
nitroxynil in the milk were monitored for up to 120 days after calving.  
Nitroxynil was detected by UHPLC-MS/MS (ultra high performance 
liquid chromatography coupled to tandem mass spectrometry).  
The present study quantified the residue concentrations of 
nitroxynil in the milk of cows which were treated by subcutaneous 
administration at the recommended dose of 10 mg nitroxynil per kg body 
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weight at the beginning of the dry period. The occurrence and the 
depletion of the residues in milk after calving was investigated. 
 
4.2  INTRODUCTION 
 
Nitroxynil is a flukicide belonging to the family of phenol 
derivatives and according to the Commission Regulation No 37/2010 (4) 
can not be used in animals from which milk is produced for human 
consumption. Until December 2009 in a few countries of the European 
Union a limited number of compounds, one of which is Nitroxynil, were 
licensed for use in animals treated during dry cow period. The probably 
of finding non compliant samples after calving is more then virtual (65) 
and for this reason products containing nitroxynil are no longer allowed 
in dairy cows. 
Nowadays there is no Maximum Residue Limit fixed for this drug 
in milk, the European Union has established MRLs for the marker residue 
Nitroxynil (4) only in bovine and ovine muscle (400 µg/kg
 -1
), liver (20 
µg/kg
 -1
), fat (200 µg/kg
 -1
) and kidney (400 µg/kg
 -1
). Aim of the study 
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was to determinate the persistence and the depletion of Nitroxynil in 
dried off cows. 
 
4.3 EXPERIMENTAL 
 
35 healthy pregnant Friesian-Holstein dairy cows from “Animal & 
Grassland Research and Innovation Centre”, Teagasc  Moorepark, 
Fermoy, Co. Cork were selected for the experiment. The cows used in 
this study, with an average body weight of 600kg, had not been treated 
with products containing nitroxynil within 12 months before the start of 
this study as documented by the farm records. The cows were treated at 
the start of the dry period, from 53 to 74 days before the expected calving 
with TRODAX 340 mg/ml (Merial ®). This corresponds to 1.5ml 
Solution for Injection per 50 kg body weight. The dose to administer was 
calculated on the basis of the estimated average body weight of the cows. 
Milk samples were taken daily for the first four days and then every three 
days for up to 120
th
 day and stored at -20°C until analysis. 
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4.4 REAGENTS AND SAMPLES 
 
Ultra-pure water (18.2 MOhm) was generated in house using a 
Millipore (Cork, Ireland) water purification system.  HPLC-grade 
methanol (MeOH) and acetonitrile (MeCN), 99.5% deuterated methanol 
(MeOH-d), and ammonium formate (puriss p.a) were sourced from 
Sigma-Aldrich (Dublin, Ireland).  Analar grades of DMSO, isopropyl-
alcohol (IPA), and glacial acetic acid (HOAc) were obtained from BDH 
Chemicals Ltd., (Poole, UK).  Pre-weighed mixtures of 4 g anhydrous 
magnesium sulphate (MgSO4) and 1 g sodium chloride (NaCl) in 50 mL 
centrifuge tubes, and 1.5 g MgSO4 and 0.5 g C18 in 50 mL centrifuge 
tubes were obtained from UCT, Inc. (Bristol, PA; USA).  Organic milk 
was purchased in supermarkets and tested for residues prior to analysis.  
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4.5 STANDARDS, INTERNAL STANDARDS AND STOCK 
SOLUTIONS 
 
Nitroxynil and 13C Nitroxynil were purchased from Sigma-Aldrich 
and Witega laboratories respectively. Primary stock standard solution was 
prepared at concentrations of 4,000 and 1,000 µg mL
-1
 for nitroxynil and 
13C Nitroxynil respectively in MeOH.  
Intermediate working standard solution was prepared at a 
concentration of 50 µg mL
-1 
for nitroxynil in MeOH. A working internal 
standard solution was prepared at 4µg mL
-1 
for 13C Nitroxynil in MeOH-
d. 
Extracted matrix calibrants were prepared by fortifying negative milk 
samples prior to extraction with a working standard mix, prepared at the 
following concentrations (in µg mL
-1
):  0.1, 0.25, 0.5, 1, 2.5, and 5; 
Standard 1 to 6 respectively.  Matrix-matched calibration curves were 
prepared by fortifying matrix blanks before extraction with 100 µL of the 
standards to give working standard curves in the sample equivalent range 
of 1 to 50 µg kg
 -1
.  
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Samples with values above the concentration of 50 µg kg
 -1 
were 
diluted with control milk. An additional four blank matrix samples 
(recovery controls) were fortified after extraction, two with Std 2 (50 µL) 
and two with Std 5 (50 µL) to monitor for loss of analytes during 
extraction.  
 
4.6 APPARATUS 
 
A glass dispenser (Dispensette® lll, Brand) was used for aliquoting 
MeCN extraction solvent, a Mistral 3000i centrifuge, micro centrifuge 
(Eppendorf), a multi-vortexer, a Caliper Life Sciences (Runcorn, UK) 
Turbovap LV evaporator, and a Transsonic 780LH ultrasonic bath were 
used for the extraction. 
Separations were performed using a Waters (Milford MA; USA) 
Acquity UPLC system comprising of a stainless steel HSS T3 analytical 
column (100 × 2.1 mm, particle size 1.8 m) equipped with an in-line 
filter unit containing a 0.2 µm stainless steel replacement filter 
maintained at a temperature of 60ºC and the pump was operated at a flow 
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rate of 0.6 mL min
-1
. Analytes were separated using a binary gradient 
elution containing a mobile phase A  water:MeCN (90:10, v/v) with 
0.01% HOAc and mobile phase B MeOH:MeCN (75:25, v/v) with 5mM 
ammonium formate. The gradient profile was as follows: (1) 0 – 0.5 min, 
100% A, (2) 5 min, 50% A, (3) 7 min, 10% A, (4) 8.5 min, 10% A, (5) 
8.51 min, 0% A, (6) 9.5 min, 0% A, (7) 9.51 min, 100% A, (8) 13 min 
100% A.  Injection volume was 5 µL. 
The veterinary drug residues and their metabolites were quantified using 
a Waters Quattro Premier XE triple quadrupole mass spectrometer 
equipped with an electrospray ionisation (ESI) interface.  The UPLC-
MS/MS system was controlled by MassLynx™ software and data was 
processed using TargetLynx™ Software (both from Waters).  
 
4.7 SAMPLE PREPARATION 
 
Milk samples (6) (10 g ± 0.1 g) were weighed into centrifuge tubes 
(50 mL) and fortified with internal standard and left to sit for 15 min.  
Acetonitrile (12 mL) was added to tube one containing MgSO4 (4 g) and 
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NaCl (1 g). The contents of tube one was added to the sample and shaken 
immediately to extract the residues into the MeCN layer. The sample was 
centrifuged for 12 min at 3,500 RPM (959 g).  A dispersive-SPE cleanup 
step was performed by pouring the supernatant from tube one into tube 
two (50 mL) containing MgSO4 (1.5 g) and C18 (0.5 g).  The samples 
were vortexed for 30 s and centrifuged for 10 min at 2,500 RPM (489 g).  
The supernatant (6 mL) and DMSO (0.25 mL) were added to a starstedt 
tube (15 mL) and vortexed for one min.  The MeCN layer was evaporated 
under nitrogen at 50°C to 0.25 mL.   
Extracts were filtered through 0.2 µm PTFE syringe filters (Whatman 
Rezist
®
) and injected onto the UPLC-MS/MS system. Any samples that 
fell outside the calibration range were diluted in negative milk and 
reanalysed. 
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4.8  RESULTS AND DISCUSSION 
 
4.8.a  Method 
 
The method used for the detection of Nitroxynil was developed 
previously (72) for 38 anthelmintic residues in milk. In this study the 
samples were only monitored for nitroxynil. The MRM window (Table 6) 
only contains two transitions, one for nitroxynil and one for 13C6 
Nitroxynil.  The following transitions were input into multiple reaction 
monitoring (MRM) windows, 288.90126.86 (m/z) and 288.90161.95 
for nitroxynil; 295126.69 for the 13C6 nitroxynil internal standard. The 
retention time, 3.46 min, was the same for both nitroxynil and 13C6 
nitroxynil that have been detected in negative ion mode. In the method 
developed by Whelan et al., the incurred samples were mostly highly 
positive and the sensitivity for negative ionization mode was not so 
acceptable. Nitroxynil was linear in the range 1 - 50 µg kg. Maximum 
concentration of the drug was 657 µg kg, which is outside the linear 
range of the calibration curve. Samples were typically 10 time more 
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concentrated then the range of the curve so, after the first quantification, 
samples were re-extracted with a dilution in organic milk (analyzed 
previously) by a factor of 1 in 10 or 1 in 5 depending on the initial 
concentration found in the first extraction. Using rapid polarity switching 
in electrospray ionization, a single injection was capable of detecting 
charged ions in a 13 minutes run time. 
 
Table 6. UPLC-MS/MS Conditions 
 
Analyte 
tR 
(min) 
Transition 
(m/z) 
Cone 
(V) 
CE 
(V) 
MRM 
window 
ESI 
Polarity 
IS 
 
Nitroxynil 
CN
O2N
OH
I
 
3.46 
 
 
 
 
 
 
 
288.90126.86 
288.90161.95 
 
 
 
 
 
 
36 
36 
 
 
 
 
 
 
24 
20 
 
 
 
 
 
 
3 
3 
 
 
 
 
 
 
- 
- 
 
 
 
 
 
 
13C 
  
 
 
 
 
 
 
 
13C 6 Nitroxynil 
     
 
3.46 
 
 
 
 
 
 
 
295126.69 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
IS 
 
 
 
 
 
 
 
 
 
 
 
81 
 
4.8.b  Persistence of nitroxynil residues 
 
The results of this study show that nitroxynil residues are very 
persistent but low in bovine milk of treated cows during the drying 
period. In two of 35 animals, were found to be detectable at 102 days 
after treatment with concentration of 2 µg kg
-1
. The cc alpha for 
nitroxynil is 0.24 µg kg
-1
. The highest levels of the drug were detected in 
two animals (Figure 16) at the 48
th
 and 53
rd
 day post treatment with 
concentrations respectively of 362 and 657 µg kg
-1
. 
Figure 16.  Depletion of Nitroxynil – time post treatment 
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The depletion profile is represented in the graph below that shows the 
reduction of the drug in the post calving period of each cow. This study 
was conducted in pregnant dairy cows at the beginning of the dry period 
because these are the target animal population for the investigated 
treatment. 
Figure 17.  Depletion of Nitroxynil - post calving 
 
 
 
The figure 18 shows the concentration of the antitrematodal drug in the 
mean of the animals, that decreases to ~ 10 µg/kg at 4 days post calving. 
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Figure 18.  Concentration of the drug in post the calving period  
 
a) average of 35 cows  
 
 
 
 
b) standard deviation 
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Table 7. Descriptive statistical parameters for the concentrations (µg/kg) of nitroxynil in 
the milk of dairy cows post administration of 10 mg nitroxynil per kg body weight at the 
beginning of the dry period - Data on animals in post-calving period. 
 
 
Cow 
No. 
 
Wt 
(kg) 
Date 
calved 
           
Day 
calved 
Cmax  
(µg/kg) 
Cmax  
(d) 
Tmax  
(d) 
<LOD  
(PT d) 
<LOD  
(PC d) 
2545 706 01/02/10 56 6.5 57 67 71 15 
2645 674 26/01/10 50 15.3 53 74 78 28 
2719 664 18/02/10 73 6.5 81 99 102 29 
2809 674 18/02/10 73 20.4 74 88 92 19 
2850 620 23/01/10 47 362.4 48 78 81 34 
2972 612 07/02/10 62 4.4 64 74 78 16 
3089 688 21/02/10 77 6.4 78 102 106 29 
3175 638 03/02/10 58 16.2 60 67 71 13 
3261 646 16/02/10 71 6 74 88 92 21 
3282 580 02/02/10 57 86.9 57 88 92 25 
3304 604 07/02/10 62 7.8 64 81 85 23 
3354 493 13/02/10 68 4.5 74 88 92 24 
3362 542 29/01/10 53 656 53 81 85 32 
3381 528 24/02/10 80 14 81 102 106 26 
3385 522 20/02/10 76 3.1 81 88 92 16 
3389 524 05/02/10 60 2.5 67 78 81 21 
3408 550 22/01/10 46 122.4 47 78 81 35 
3429 662 23/01/10 47 35 47 64 67 20 
3494 632 18/02/10 73 6.9 81 88 92 19 
3589 500 31/01/10 55 19.7 57 81 85 30 
3592 584 26/01/10 50 22.6 53 81 85 35 
3610 588 26/01/10 50 39.7 53 85 88 38 
3611 526 19/01/10 43 81.7 49 78 81 38 
3625 544 28/01/10 52 13.3 57 81 85 33 
3689 598 01/02/10 56 26.3 57 81 85 29 
3773 544 09/02/10 64 7.1 67 71 74 10 
4247 732 16/02/10 71 5.6 74 81 85 14 
8116 720 09/02/10 64 24.1 67 81 85 21 
8201 702 29/01/10 53 7.1 57 74 78 25 
8229 672 15/02/10 70 1.6 74 78 81 11 
8240 634 07/02/10 62 28.4 67 94 99 37 
8259 650 15/02/10 70 8.6 71 88 92 22 
8269 742 03/02/10 58 27.4 60 92 94 36 
8285 574 27/01/10 51 11.6 53 74 78 27 
8295 640 24/01/10 48 237.4 48 71 74 26 
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4.9 CONCLUSIONS 
 
Nitroxynil residues were found to very persistent in milk compared 
to other anthelmintic drug residues (65-81). When dairy cows are treated 
with Trodax 340 mg/ml Solution for injection at the highest 
recommended dose of 10 mg nitroxynil per kg body weight at the 
beginning of a dry period (about 53 to 80 days before calving – expected 
calving dates), residues of this flukicide are quantifiable in the milk of the 
35 cows until at least 13 days after calving (decision limit - cc α = 0.24 
µg kg
-1
).  
 Highest concentrations of the drug were detected at the first 
milkings and ranged from 656 µg kg in the cow 3362 to 362 µg kg in the 
cow 2850 at 53
rd
  and 67
th
 day after treatment respectively. Nitroxynil 
residues were below the limit of detection of the method between 67
th
 and 
106
th
 day post treatment.  
This could due to the size difference in body compartments and the 
amount of fat present in each animal. However, there was considerable 
variation in levels between animals, this could be due to size difference in 
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body compartments and the amount of fat of each animal.  The age and 
health of the animal also can have an effect on the results, the drugs 
behave differently in animals with/without parasitic infections. 
 In conclusion highest concentrations of nitroxynil occur in the 
milk produced shortly after calving. This colostrum milk is not suitable 
for human consumption and is collected separately from the milk that 
enters the bulk tank on the dairy farm. After the colostrum period, this is 
from about 3 days after calving, the concentrations in milk decrease to 10 
µg kg
-1
or below and residues are non-detectable 10 to 38 days post-
calving. The results of this study could be interesting for the 
establishment of a Maximum Residue limit for nitroxynil in bovine milk.  
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